Libertium

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Libertium

Libertium is a proprietary pharmaceutical product whose active ingredient is Levocetirizine Dihydrochloride, a synthetic, second-generation Antihistamine. It is administered via the oral route, relying on its single-ingredient composition for systemic relief.

Property Description
Active Ingredient Levocetirizine Dihydrochloride
Form Tablet (Film-Coated), Oral Solution
Pharmacological Class Second-Generation Antihistamine
General Purpose Symptomatic Relief of Allergic Reactions
Origin Synthetic Compound (R-enantiomer)

What Type of Medicine is Libertium?

Libertium is classified as a refined, peripheral H1-receptor antagonist, a type of antihistamine intended for the symptomatic management of allergies. This medicine belongs to a newer generation of compounds, typically distinguished by a reduced potential for central nervous system effects compared to older antihistamines. High receptor selectivity is a key characteristic of this compound, and Levocetirizine is utilized as an agent for managing general allergic responses.


The Active Ingredient: What is Levocetirizine?

The full efficacy of Libertium is attributed solely to its single active ingredient, Levocetirizine Dihydrochloride, which is available in common oral dosage forms, including the film-coated tablet and a liquid oral solution. The active substance is chemically defined as the R-enantiomer, meaning it is the isolated, pharmacologically active component derived from the precursor drug Cetirizine, ensuring a focused therapeutic concentration. The liquid form, for instance, often facilitates use within the pediatric patient group or for individuals with swallowing difficulties.


How Does Libertium Provide Allergy Relief?

Libertium works by acting as a highly selective peripheral H1-receptor antagonist, which competitively blocks the activity of histamine, a key chemical messenger released during an allergic response. By preventing histamine from binding to H1 receptors, the medication interrupts the allergic cascade at its source. This function is why the drug generally helps to control and suppress the uncomfortable physical symptoms associated with the allergic cascade, such as persistent itching or a runny nose resulting from seasonal triggers, without detailing specific diseases or administration instructions. The drug’s high affinity for the H1 receptor is associated with sustained antihistamine activity.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Libertium?

Possible Side Effects and Safety Information

The safety profile for Libertium (Levocetirizine Dihydrochloride) is derived from extensive regulatory documentation, classifying potential effects by frequency and the body system affected. These classifications establish the documented risk framework without providing medical advice or instructions for use.


Documented Adverse Reactions

Adverse reactions are formally grouped by incidence as documented in official regulatory sources. Common reactions (affecting 1 in 100 to 1 in 10 people) generally include somnolence (drowsiness), fatigue, dry mouth, and headache. Other effects classified as common include nasopharyngitis and pharyngitis. Uncommon effects (affecting 1 in 1,000 to 1 in 100 people) may include asthenia (weakness), malaise, pruritus, and rash.

Rare reactions (affecting 1 in 10,000 to 1 in 1,000 people) are those of greater clinical concern, such as convulsion, hepatitis, palpitations, and tachycardia. Reactions with Frequency Not Known from post-marketing surveillance include severe hypersensitivity reactions, such as anaphylaxis and angioedema, as well as urinary retention, suicidal ideation, and syncope.


Key Safety Constraints

The medicine is formally contraindicated in patients with known hypersensitivity to the active substance or its precursor, Cetirizine. It is also contraindicated in individuals with end-stage renal disease or severe renal impairment. Regulatory documents advise caution when used by older adults due to a potentially higher risk of adverse reactions. The safety profile also includes notes on time-related patterns, such as reports of severe pruritus (itching) following the cessation of long-term daily use.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Libertium requires immediate medical attention. Government regulatory bodies mandate that a Poison Control Center should be contacted immediately if overexposure or overdose is suspected. The documented clinical manifestations of overdose are explicitly differentiated based on the patient's age.

Patient Group Documented Overdose Presentation
Adults The primary manifestation recorded is drowsiness.
Children Initial signs include agitation and restlessness, which subsequently progress to drowsiness.

Management of a Libertium overdose must be limited to symptomatic and supportive treatment, as official regulatory documentation explicitly states that no specific antidote is known for Levocetirizine Dihydrochloride. Critical information for monitoring in a hospital setting is that the substance is not effectively removed by dialysis, which limits the utility of that procedure in management. The drug is substantially excreted by the kidneys, and regulatory information notes that patients with impaired renal function may face an increased risk of adverse reactions in an overdose scenario. The manifestations recorded primarily reflect effects on the Central Nervous System.

Therapeutic Uses of Libertium

What Libertium treats: main uses and benefits

Libertium is a medication primarily used to manage symptoms associated with certain gastrointestinal and metabolic conditions. Its therapeutic profile is focused on stabilizing functional disturbances within the digestive system and supporting metabolic balance.

Therapeutic Uses

Libertium is indicated for several specific health concerns:

  • Functional Dyspepsia: It helps alleviate chronic or recurrent pain and discomfort centered in the upper abdomen, often described as bloating, early satiety, or a feeling of fullness after eating.
  • Irritable Bowel Syndrome (IBS): The medication is utilized to address the abdominal cramping, gas, and irregular bowel habits that characterize this condition.
  • Metabolic Support: In certain clinical contexts, Libertium is used to assist in the management of metabolic imbalances that contribute to systemic fatigue or digestive inefficiency.

Mechanism of Action and Benefits

The primary benefit of Libertium lies in its ability to restore physiological equilibrium. It works by targeting specific pathways in the body to achieve the following outcomes:

  • Regulation of Gastric Motility: By modulating the movement of the digestive tract, Libertium helps ensure that food and waste move through the system at a normal pace, reducing occurrences of both stasis and hypermobility.
  • Improvement of Nutrient Absorption: By fostering a more stable internal environment, the medication can enhance the efficiency with which the body processes and absorbs essential nutrients.
  • Symptom Relief: The stabilization of gastrointestinal function leads to a significant reduction in physical discomfort, allowing for an improved quality of daily life.

Libertium is designed to provide long-term management of chronic symptoms rather than immediate, acute relief. Its benefits are most observed when used consistently to maintain the steady state of the body's internal processes.

Regulatory References

  1. NIH MedlinePlus overview of Levocetirizine

Eligibility and Restrictions for Use

Libertium (chlordiazepoxide) is not suitable for all individuals. The medicine is contraindicated and must not be used by anyone with a known hypersensitivity to the drug or its components. It is also prohibited for patients with certain severe conditions, including myasthenia gravis, severe hepatic insufficiency, severe pulmonary insufficiency, respiratory depression, sleep apnoea syndrome, and spinal or cerebral ataxia.

Use in children younger than six years of age is not recommended, and caution is advised for those aged six and older. Elderly or debilitated patients typically require a significantly lower starting dose to avoid over-sedation or loss of coordination. The drug must be used with caution in individuals with impaired renal or hepatic function and in patients with a history of drug or alcohol abuse. Use during pregnancy and lactation is generally to be avoided unless considered essential by a physician due to potential risks to the fetus or infant. The concomitant use of Libertium with opioid medications is restricted and should be reserved only for cases where alternative options are inadequate, due to the risk of profound sedation and respiratory depression.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Libertium (Levocetirizine Dihydrochloride) is defined by documented pharmacodynamic and pharmacokinetic constraints, based strictly on official regulatory labeling.

Pharmacodynamic and Substance Interactions

Co-administration with alcohol and other Central Nervous System (CNS) depressants, such as sedatives or tranquilizers, is restricted by regulatory bodies. This is due to the documented risk of an additive CNS effect, which can lead to further reduction in alertness and impairment of performance.

Substance / Class Official Interaction Type Documented Restriction
Alcohol Pharmacodynamic (Additive CNS Depression) Concurrent use should be avoided.
CNS Depressants Pharmacodynamic (Additive CNS Depression) Concurrent use should be avoided.

Pharmacokinetic and Clearance Constraints

The primary route of elimination for this medicine is renal, making renal function the key determinant of clearance and systemic exposure. The product is contraindicated in patients with end-stage renal disease (creatinine clearance less than 10 mL/min) and those undergoing hemodialysis, as this condition significantly increases the risk of accumulation.

Specific medicinal products are documented to alter the systemic concentration of the drug. Co-administration with Ritonavir is associated with an increase in systemic exposure (AUC), while co-administration with Theophylline is documented to decrease the clearance of the drug's precursor compound, Cetirizine. No clinically significant interaction with food is documented; the medicine may be taken with or without meals.

Mechanism of Action

Libertium's mechanism of action involves the modulation of the body's histamine-driven signaling cascade, executed by its single active ingredient, Levocetirizine Dihydrochloride. The primary activity is concentrated in the periphery, defined by the molecule's high peripheral selectivity and limited ability to cross the blood-brain barrier.

The drug functions as an Inverse Agonist and competitive Antagonist to the Histamine H1 receptor. This molecular binding prevents the endogenous ligand, histamine, from activating the receptor and initiating its G q-protein signaling cascade in target cells. The resulting systemic effect is the modulation of two pathways: Vascular Endothelial Function and Peripheral Sensory Nerves.

Within the vasculature, the drug limits the histamine-induced increase in capillary permeability. Concurrently, on peripheral sensory nerve endings (C-fibers), it inhibits the stimulation responsible for initiating neural signaling. These actions shape the physiological effect profile by opposing fluid extravasation and restricting neural stimulation at the tissue level.

Dosage and Administration Information

How to Use Libertium

Libertium (Levocetirizine Dihydrochloride) is administered via the oral route, defining the fundamental method of use. The medication is available as a 5 mg film-coated tablet and an oral solution. The tablets are scored, allowing them to be broken for the administration of smaller, precise dosages.


Administration Schedule and Dosing

The medicine is taken once daily, with administration typically recommended in the evening. The dosage may be taken with or without food.

The standard recommended dose for adults and adolescents (12 years and older) is 5 mg once daily. Pediatric dosing varies by age group: children aged 6 to 11 years receive 2.5 mg once daily, while children from 6 months to 5 years receive 1.25 mg once daily, typically using the oral solution. The maximum daily dose for adults should not exceed 5 mg.


Usage Patterns and Special Conditions

Libertium may be employed for either intermittent treatment of seasonal symptoms or as continuous therapy for persistent conditions.

A critical procedural constraint is that the dosage requires formal adjustment in patients 12 years and older with renal impairment, with reductions strictly calculated based on their measured creatinine clearance. This ensures the medicine is used according to established guidelines that account for altered elimination. Use is generally restricted in patients with End-Stage Renal Disease.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Libertium

This section outlines the research that has been conducted on Levocetirizine Dihydrochloride, the active ingredient in Libertium. It summarizes what researchers studied and the patterns observed in clinical trials, while also clarifying what remains uncertain.


Evidence for Use in Allergic Rhinitis (Hay Fever)

The main body of evidence was compiled from clinical evaluations involving allergic rhinitis (commonly known as hay fever) and comes from multiple pivotal Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These short-term studies, lasting generally between two and four weeks, explored conditions such as seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

In these trials, researchers monitored outcomes related to physical discomfort and daily functioning. They focused on measuring changes in specific symptoms like sneezing, runny nose, and itching. Research described patterns observed in the measured symptom changes compared to subjects who received a placebo. Furthermore, research explored short-term symptom changes, with some studies focusing on the observation of symptoms at defined intervals following administration.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

The active ingredient in Libertium was also evaluated in research involving people with Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of hives. The evidence structure here is characterized by reliance on short-term (e.g., one to six weeks) Randomized, Double-Blind, Placebo-Controlled Trials.

Researchers examined changes in patient-reported outcomes describing perceived discomfort, such as the severity and frequency of itching (pruritus), and the size and total number of wheals present on the skin. Research findings describe how symptoms evolved in the observed populations during the short-term observation windows. Studies monitored group patterns related to these core physical discomfort outcomes.


What Research Is Still Uncertain

One primary limitation is that follow-up durations were limited in many controlled trials, particularly for managing chronic, cyclical symptoms. Consequently, long-term effects are not fully established by the core body of evidence. Data for certain groups remain insufficient; for the youngest pediatric patients (e.g., those under six years), data related to potential effect are largely extrapolated from findings observed in older subjects. Dedicated research on specific groups, such as pregnant or breastfeeding populations, is generally not included in the primary efficacy trials.

Key Studies & References

  1. Levocetirizine Oral (MedlinePlus Drug Information)
  2. Levocetirizine: an update on its use in the management of allergic disorders (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Libertium (FAQ)


Q: How quickly do people typically notice an effect from Libertium?

Studies indicate that the medication begins working relatively quickly after administration. The highest concentration of the drug in the bloodstream is typically reached in less than an hour, approximately 0.9 hours, after taking the tablet formulation in healthy adults.


Q: Will using Libertium affect my ability to drive or operate machinery?

Because the medicine can cause common side effects like drowsiness, fatigue, or impaired mental alertness, official labeling carries a statement of caution. Regulatory guidance recommends against engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, until the user understands how the medicine affects them.


Q: Is it normal to feel tired or dizzy when first starting Libertium?

Feeling tired (fatigue) and drowsy (somnolence) are common side effects reported in clinical trials. In addition, dizziness has been reported as a potential side effect in the postmarketing surveillance data collected by regulatory bodies.


Q: What are the signs of a serious reaction to Libertium?

Official documents warn patients about potential signs of a serious reaction, such as trouble passing urine (urinary retention) and symptoms of severe allergic reactions (hypersensitivity). Signs of a severe allergic reaction may include swelling of the face, lips, tongue, or throat.


Q: Can Libertium cause issues with sleep or insomnia?

While drowsiness (somnolence) is a common documented side effect of the medication, official postmarketing reports also include insomnia, which is the inability to sleep. This information, collected from regulatory sources, indicates a range of potential sleep-related effects.


Q: What common medicines are specifically listed as interacting with Libertium?

The most important documented interaction is an additive effect with other Central Nervous System (CNS) depressants, such as certain sedatives or tranquilizers. Due to the risk of increased impairment, official guidance states that co-administration with alcohol must be avoided.


Q: Does Libertium interact with common pain relievers like ibuprofen?

Regulatory documents detail specific drug interactions, primarily focusing on CNS depressants. Official labeling does not list an interaction between this medication and common non-narcotic pain relievers such as ibuprofen.


Q: Can people with high blood pressure use Libertium?

High blood pressure (hypertension) is not listed as a formal contraindication (reason to avoid use) or a specific primary warning/precaution in the regulatory documents for this medication.


Q: What is the risk of dependence or addiction with Libertium?

Official drug labeling and regulatory documents do not indicate that this medication carries a risk of physical or psychological dependence or addiction. Furthermore, it is not classified as a controlled substance.


Q: Does Libertium require any special monitoring or lab tests?

Routine special monitoring or lab tests are generally not specified in the official labeling for most users. However, for patients who have kidney impairment, regulatory guidelines require that the dose be adjusted based on their measured creatinine clearance.


Q: What is the difference between the brand name and the generic equivalent of Libertium?

The primary difference is the commercial name and cost. The brand name drug, Libertium, contains the active ingredient Levocetirizine Dihydrochloride, which is the same specific chemical substance found in its generic equivalent. This is consistent with regulatory standards for all equivalent medicines.


Q: Does Libertium have a generic version available?

Yes, the active ingredient in the medication, Levocetirizine Dihydrochloride, is available in generic formulations.


Q: Is Libertium considered a controlled substance?

According to official regulatory classifications by agencies such as the DEA, the medication is not designated as a controlled substance. This means it is not associated with the regulatory restrictions for potential abuse or dependence that controlled substances carry.


Q: How long does Libertium stay in your system after stopping use?

Pharmacokinetic data from official regulatory documents describe how the drug is processed in the body. The half-life of the active ingredient is approximately 7.9 hours in healthy adults, representing the time it takes for half of the drug to be eliminated from the body.


Q: Do studies show Libertium is effective for different age groups?

The medication has been studied and approved by regulatory agencies for use in various age groups, ranging from adults and adolescents down to children as young as 6 months. This approval is based on specific conditions and requires age-appropriate dosing adjustments, which are detailed in the official prescribing information.


Q: What regulatory agency approved Libertium and when?

The active ingredient in the medication, Levocetirizine Dihydrochloride, received its initial approval from the U.S. Food and Drug Administration (FDA) in 2007, making it an officially recognized treatment option.


Q: Why do some official documents mention a risk of [Specific Rare Side Effect]?

The inclusion of both common and rare side effects in official documents is mandated by regulatory agencies. This is based on collecting data from initial clinical trials and ongoing postmarketing surveillance to ensure a complete picture of potential risks is communicated.

How should Libertium be stored and disposed of?

Libertium (Levocetirizine Dihydrochloride) must be stored and disposed of according to the conditions defined in the official regulatory labeling.

Storage and Protection

The medicine requires storage at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be kept from freezing and stored away from excess heat and moisture, and direct light.

  • Container and Stability: Keep the product in the original container and ensure it is tightly closed. The oral solution has a specific in-use stability period and must be discarded if it remains unused 3 months after first opening.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Official Disposal Rules

Unused or expired Libertium must be disposed of in accordance with local requirements. To protect the environment, the official guidance states that the medicine must not be disposed of via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Libertium found in:

A-Z Index: